Influx Healthtech (NSE:INFLUX) Operating Income: ₹279 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:INFLUX Influx Healthtech Ltd NSE:INFLUX
22 GF Score
Price ₹283.70
! 4 Warning Signs
View Full Analysis

What is Influx Healthtech Operating Income?

Influx Healthtech NSE:INFLUX -1.70% 22 Operating Income is ₹279 Mil as of Mar. 2026. GuruFocus rates NSE:INFLUX with a GF Score™ of 22/100. The stock has 4 warning signs investors should review.

Influx Healthtech's Operating Income for the six months ended in Mar. 2026 was ₹149 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was ₹279 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Influx Healthtech's Operating Income for the six months ended in Mar. 2026 was ₹149 Mil. Influx Healthtech's Revenue for the six months ended in Mar. 2026 was ₹791 Mil. Therefore, Influx Healthtech's Operating Margin % for the quarter that ended in Mar. 2026 was 18.82%.

Influx Healthtech's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Influx Healthtech's annualized ROC % for the quarter that ended in Mar. 2026 was 33.21%. Influx Healthtech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 48.80%.


Influx Healthtech  (NSE:INFLUX) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Influx Healthtech's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=297.698 * ( 1 - 25.65% )/( (576.766 + 756.114)/ 2 )
=221.338463/666.44
=33.21 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1135.402 - 193.018 - ( 365.618 - max(0, 232.918 - 825.585+365.618))
=576.766

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1237.03 - 206.263 - ( 274.653 - max(0, 227.116 - 814.627+274.653))
=756.114

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Influx Healthtech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=286.826/( ( (247.358 + max(216.115, 0)) + (402.115 + max(309.983, 0)) )/ 2 )
=286.826/( ( 463.473 + 712.098 )/ 2 )
=286.826/587.7855
=48.80 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(340.988 + 106.286 + 1.759) - (193.018 + 0 + 39.9)
=216.115

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(337.804 + 159.327 + 39.968) - (206.263 + 0 + 20.853)
=309.983

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Influx Healthtech's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=148.849/790.797
=18.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Influx Healthtech Operating Income Related Terms


Influx Healthtech Operating Income Historical Data

* Premium members only.

The historical data trend for Influx Healthtech's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Influx Healthtech Operating Income Chart

Influx Healthtech Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Operating Income
60.51 98.12 151.52 178.98 278.64

Influx Healthtech Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Operating Income Get a 7-Day Free Trial 0.00 78.39 100.59 129.79 148.85
NSE:INFLUX
22GF Score
Influx Healthtech Ltd NSE:INFLUX
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Influx Healthtech Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹279 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of ₹279 Mil mean?
Influx Healthtech (NSE:INFLUX) has a Operating Income of ₹279 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Influx Healthtech and its competitors.
Is Influx Healthtech's Operating Income too high?
Influx Healthtech's current Operating Income is ₹279 Mil. Overall, Influx Healthtech has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's Operating Income compare to ZTS?
Influx Healthtech's Operating Income of ₹279 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Influx Healthtech and its competitors. Influx Healthtech's current Operating Income is ₹279 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current Operating Income of ₹279 Mil. The current Operating Income is ₹279 Mil. Influx Healthtech's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current Operating Income is ₹279 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Influx Healthtech Business Description

Address Plot No. 856, 109, Ghanshyam Enclave Premises Co-op Society, Behind Laljipada Police Chowky, Kandivali West, Mumbai, MH, IND, 400067
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
22GF Score

Get the complete analysis for NSE:INFLUX

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹283.70
Price